Speaker Profile

M.D., Ph.D., Chief Medical and Scientific Officer, NX Prenatal

Dr. Rosenblatt leads the clinical assay development efforts for NX Prenatal, leveraging more than 29 years of clinical and biomedical research and development experience in multiple settings, including academia, biotech, startups, and clinical practice. Prior to joining NX Prenatal, he was Chief Scientific Officer, Chief Medical Officer, and Clinical Laboratory Director at CompanionDx's CLIA/CAP certified reference lab. Among other appointments, he has served as Director of the Center for Clinical Proteomics at the Brown Foundation Institute of Molecular Medicine, as well as the Director of the UT Health Science Center at Houston's Center for Clinical and Translational Sciences Proteomics Core. Dr. Rosenblatt also serves as Associate Professor in the Division of Oncology, Department of Internal Medicine at UT Health and the McGovern Medical School and Associate Adjunct Professor in the School of Health Professions at the MD Anderson Cancer Center. Earlier in his career, Dr. Rosenblatt was co-founder and Laboratory Director of Risk Assessment Laboratories, which partnered with Perkin-Elmer to develop adverse pregnancy outcome biomarkers.

Women's Health Showcase:
NX Prenatal

NX Prenatal utilizes proprietary exosome-based liquid biopsy techniques to create breakthroughs in maternal-fetal diagnostics. Our NeXosome® Platform has yielded Preterm Birth and Preeclampsia biomarker panels at week 10-12 of pregnancy in asymptomatic women to support personalized care pathways.

Exosomes: Decoding Maternal-Fetal Cross Talk
Maternal-fetal cross-talk is mediated by exosomes, which actively support a number of physiological systems, including regulating the immune protection of the fetus. NX Prenatal has demonstrated that the profiling of exosomal-bound proteins circulating in pregnant women provides early markers predicting preterm birth and preeclampsia, and also provides new insight into the molecular pathways associated with such outcomes.

 Session Abstract – PMWC 2022 Silicon Valley

Track Co-Chairs:
Aleksandar Rajkovic, UCSF

Researchers have long been recognizing the uniqueness of women’s health and its substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared to men. This Track will focus on the following topics related to Women’s Health:

  • Intro to Women's Health
    - Aleksandar Rajkovic, UCSF
  • US Regulatory/Personalized Medicine and Women's Health
    Session Chair: Kathryn G. Schubert, SWHR
    - Kaveeta Vasisht, FDA
  • Reproductive Health
    - Hakan Cakmak, UCSF
    - Laura Jelliffe-Pawlowski, UCSF
  • Pregnancy (PANEL)
    Session Chair: Yoel Sadovsky, University of Pittsburgh
    - Virginia D. Winn, Stanford
    - Ananth Karumanchi, Cedars-Sinai Medical Center
    - Mira Moufarrej, Stanford University
  • Carrier Screening: Perspective on the new ACMG Practice Resource
    - James D Goldberg, Women's Health Medical Affairs
  • Biological Sex Differences in Disease + Inclusion of Women in Clinical Research/Innovation
    - Rhonda Voskuhl, UCLA
  • Cardiovascular Health
    - Nisha Parikh, UCSF
    - Jennifer Ann Tremmel, Stanford
  • Bone Health/Osteoporosis & Menopause
    Session Chair: Risa Kagan, UCSF, Sutter Health
    - Danit Ariel, Stanford
    - Massimiliano (Max) de Zambotti, SRI International
  • Showcase
    - Carrie Haverty, Mirvie
    - Kevin P. Rosenblatt, NX Prenatal
    - Ripudaman Singh, ARCEDI Biotech
    - Claire Tomkins, Future Family
    - Donne Russell, Precia Group
    - Adam de la Zerda, Visby Medical, Inc.